logo
Human brains contain spoonful of microplastics, dementia risk skyrockets: Study

Human brains contain spoonful of microplastics, dementia risk skyrockets: Study

Yahoo05-03-2025

A disturbing new finding shows microplastics have infiltrated human brain tissue, raising serious questions about our health.
It's been discovered that human brains accumulate a surprisingly large amount of microplastics and nanoplastics – equal to a spoonful. Even more concerning, these levels are 3 to 5 times higher in individuals with dementia.
Building on findings from Nature Medicine, a detailed commentary was recently released in Brain Medicine on this invisible health threat.
"The dramatic increase in brain microplastic concentrations over just eight years, from 2016 to 2024, is particularly alarming," notes Dr. Nicholas Fabiano from the University of Ottawa's Department of Psychiatry, lead author of the Commentary.
"This rise mirrors the exponential increase we're seeing in environmental microplastic levels," added Fabiano.
These tiny plastic fragments, resulting from the breakdown of larger plastics, have infiltrated virtually every corner of the globe.
They are found in the deepest ocean trenches, within the tissues of marine organisms ranging from plankton to whales, and have even been detected in the air and snow of remote mountain peaks.
This widespread distribution highlights the alarming ability of microplastics to travel through air, water, and food chains.
The study revealed that brain tissue contains much higher concentrations of microplastics and nanoplastics (MNPs) – 7 to 30 times more – compared to other vital organs, such as the liver and kidneys.
The main concern lies with nanoplastics – particles smaller than 200 nanometers. The small size raises the possibility that they can cross the blood-brain barrier, which could have implications for neurological health.
Researchers analyzed brain tissue from autopsies, comparing samples from 2016 to 2024. They specifically analyzed the frontal cortex, an area of the brain directly behind the forehead.
The study identified 12 different types of plastic polymers, with polyethylene being the most prevalent in the brain tissue samples. Polyethylene is widely used in packaging and containers like bottles and cups.
The commentary suggests a simple yet effective way to reduce microplastic intake: switching bottled water to filtered tap water.
This change alone could decrease annual microplastic consumption from 90,000 particles to just 4,000.
"Bottled water alone can expose people to nearly as many microplastic particles annually as all ingested and inhaled sources combined. Switching to tap water could reduce this exposure by almost 90%, making it one of the simplest ways to cut down on microplastic intake," said Dr. Brandon Luu, an Internal Medicine Resident at the University of Toronto.
Other key sources of microplastic intake include plastic tea bags and improper food storage/heating. Plastic tea bags release millions of tiny particles during brewing, and heating food in plastic containers.
"Heating food in plastic containers—especially in the microwave—can release substantial amounts of microplastics and nanoplastics," the author explained.
"While these changes make sense, we still need research to confirm whether lowering intake leads to reduced accumulation in human tissues," Luu added.
Researchers have also been investigating how the body might eliminate microplastic compounds, with initial findings suggesting sweating could play a role.
If left unchecked, this issue could represent a major, unforeseen environmental health crisis.
"The commentary calls for urgent research priorities, including establishing clear exposure limits and assessing long-term health consequences of microplastic accumulation,' the press release noted.
The peer-reviewed Commentary has been published in Brain Medicine.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

Yahoo

time2 days ago

  • Yahoo

HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentationat the American Society of Clinical Oncology (ASCO) 2025 annual meeting, with select results simultaneously published in Nature Medicine. The findings highlight HER3-DXd as a potential novel treatment for patients with secondary central nervous system involvement. CHICAGO, May 30, 2025 /PRNewswire/ -- Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. Furthermore, some patients with breast cancer who had previously received antibody-drug conjugates also responded to HER3-DXd, highlighting the potential of HER3-DXd to overcome resistance and expand treatment options in refractory disease. Intracranial activity was also observed in patients with aNSCLC and brain metastases, intracranial responses were observed in patients whose tumors contained no activating driver mutations as well as patients whose tumors contained an EGFR or KRAS mutation. Overall, the data suggest that HER3-DXd may offer a novel treatment option for patients with secondary CNS involvement. KEY HIGHLIGHTS OF THE TUXEDO-3 STUDY The TUXEDO-3 study aimed to assess whether HER3-DXd could be an effective treatment option for patients with mBC and aNSCLC with active brain metastases, and leptomeningeal disease from solid tumors. The study met its primary objectives, with 23.8% and 30% patients achieving intracranial responses in active brain metastases from patients with mBC and aNSCLC, respectively, and 65% patients with leptomeningeal disease alive after 3 months. Side effects were consistent with previous studies using HER3-DXd. Tests evaluating quality of life and neurocognitive functions showed that patients remained stable or improved during the treatment follow-up. The primary objectives consisted of assessing the intracranial objective response rate in patients with active brain metastases from mBC and aNSCLC, and determining the number of patients with leptomeningeal disease alive after 3 months of starting the treatment. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients," stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: "Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients." ABOUT UMMET CANCER NEEDS Unmet cancer needs refer to gaps in resources, support, and treatment options that exist for cancer patients. Addressing unmet cancer needs is crucial to improving quality of life and outcomes for cancer patients. Through the collaborative work of healthcare providers, policymakers, and patient advocacy groups unmet cancer needs can be identified to help provide patients with comprehensive and quality care. SHOWCASING PROMISING COLLABORATIVE TRIALS AT ASCO In addition to the oral presentation of TUXEDO-3, MEDSIR will present both ADELA and WIN-B studies in poster format. The ADELA clinical trial is an ongoing international phase III study in collaboration with The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients. The study is being conducted across multiple countries which combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression. Regarding WIN-B, is a phase Ib/II, multi-center investigator-initiated trial, evaluating the safety and preliminary efficacy of combining Debiopharm's selective WEE1 inhibitor, Debio 0123 and Gilead's antibodydrug conjugate Trodelvy® (sacituzumab govitecan-hziy) in advanced HR+/HER2- and triple-negative breast cancers. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind. ABOUT MEDSIR Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: View original content to download multimedia: SOURCE MEDSIR Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GLP-1s Treat and Even Reverse Some Forms of Liver Disease
GLP-1s Treat and Even Reverse Some Forms of Liver Disease

Medscape

time4 days ago

  • Medscape

GLP-1s Treat and Even Reverse Some Forms of Liver Disease

In the past two decades, the global prevalence of metabolic dysfunction–associated steatohepatitis (MASH) has increased dramatically as a result of the obesity epidemic. Researchers project that by 2040, rates of MASH will increase by 55%. Prior to that most liver diseases were caused by alcohol use and hepatitis C, a viral infection that primarily affects the liver. MASH, a preventable form of liver disease previously called nonalcoholic fatty liver disease, is caused by a buildup of visceral fat cells that accumulate on top of the internal organs, in this case the liver, and keep it from functioning properly. The liver's primary role is to filter blood, nutrients, and bile used for digestion, as well as to remove toxins from the body. Excess fat cells blanket the liver and keep it from working at full capacity. Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they reside. Over time, these fat cells can cause cirrhosis of the liver, or permanent scarring. Once patients reach this stage, the only option is a liver transplant. New Research on Glucagon-Like Peptide 1 (GLP-1) Agonists and MASH Until recently, the lone treatment for early-stage MASH was weight loss to reduce the number of fat cells that surround the internal organs. But new research has shown that GLP-1 agonists can reduce and even reverse the condition. In a study published last month in The New England Journal of Medicine , researchers were able to show that semaglutide resolved fatty liver and inflammation in over 60% of cases and decreased scar tissue in just over a third of patients. 'These findings suggest that semaglutide may prevent fatty liver disease from progressing to cirrhosis and can indeed reverse the course of the disease,' said Arun J. Sanyal, MD, study author and director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University in Richmond, Virginia. Another study published last year in JAMA Internal Medicine had a similar finding, showing that GLP-1 agonists were associated with less progression of the disease and reduced mortality in patients with MASH and diabetes. Another large-scale observational study published in Nature Medicine found that GLP-1s reduced the risk for hepatic failure, which occurs when the liver is unable to perform basic functions, as well as liver cancer, both of which are downstream consequences of MASH. How GLP-1s Improve Liver Function 'These medications reduce fat burden, which results in fat loss everywhere, including around the liver,' said Ziyad Al-Aly, MD, an assistant professor in the Division of General Medicine & Geriatrics at Washington University School of Medicine in St. Louis and author of the recent study in Nature Medicine . 'When fat cells are reduced in size and volume, the normal liver cells have more room to grow and function.' Ziyad Al-Aly, MD These medications also seem to work on reducing the inflammation and oxidative stress caused by metabolic disease, which allows for a better environment for the liver to function. 'Fat is not an inert tissue, it's metabolically active, causing a slow burn to all the cells surrounding it,' said Al-Aly. These medications keep the disease from progressing and reduce scarring, which improves the damage that's already been done, he said. Changing How Primary Care Physicians Diagnose Liver Disease Primary care physicians are most often the first line of defense against liver disease, and as a result, they need to be vigilant in the way that they screen for the condition, said Charu Sawhney, DO, MPH, an internal medicine physician with Harbor Health in Round Rock, Texas. Physicians need to be aware that even if liver enzymes appear even slightly elevated, there still could be a reason to utilize these medications to prevent later-stage MASH. Charu Sawhney, DO, MPH 'Normal levels for liver enzymes in some patients can be lower than what labs show,' said Sawhney. This is especially true if a patient has other metabolic risk factors such as diabetes, obesity, or high cholesterol. If liver enzymes continue to go up even after diet and lifestyle changes, patients might require liver imaging, specifically a wave-based ultrasound called elastography, which measures the elasticity or stiffness of tissues on the liver and can judge if certain portions of it have scarred or hardened. When liver cells change texture and become harder, the scan can estimate levels of fibrosis and, therefore, the stage of MASH that a patient is in. Additionally, the severity of fatty liver disease depends on other factors besides weight and can sometimes be surprising. 'How bad fatty liver disease is in a patient isn't always related to how much weight someone has gained,' said Carolynn Francavilla, MD, a nationally recognized obesity physician who owns and operates Green Mountain Partners for Health and Colorado Weight Care, both in Denver. It's important for physicians to realize that some patients with fatty liver disease might not have obesity as would be expected. For these patients, adipose tissue seems to accumulate on the liver before it does on other parts of the body. This could be related to the quality of our food system, including the use of sugar substitutes like high fructose corn syrup, which research has shown is even harder on the liver. There might also be a genetic propensity toward fat storage around the organs. A New Way to Treat MASH If indeed GLP-1s are a potential treatment in those with MASH, this might also change the way that primary care physicians treat these patients and how the medication is prescribed in those with earlier stages of the disease, said Francavilla. Right now, there's not an official approval from the US Food and Drug Administration (FDA) for prescribing GLP-1s in patients with MASH, but Francavilla hopes that it's forthcoming. 'It will be really exciting to have these medications as a treatment option because right now there's only one medication, and it's for people who have pretty advanced fatty liver disease,' said Francavilla. This medication, called resmetirom , is approved by the FDA to target a protein in the liver to reduce fat and inflammation and scarring. But GLP-1s can be used much earlier to prevent the condition. 'With so many cases of MASH happening so much younger, it's a disease that physicians really need to take seriously,' said Sawhney. 'If we want to catch this disease at the early stages when we can still do something about it, it's most likely going to be primary care physicians who see it.'

New Research Links Microplastics to Brain Health — Echo's Whole Home Filter Provides Protection
New Research Links Microplastics to Brain Health — Echo's Whole Home Filter Provides Protection

Yahoo

time5 days ago

  • Yahoo

New Research Links Microplastics to Brain Health — Echo's Whole Home Filter Provides Protection

Echo's Advanced Filtration System Tackles Microplastic Contamination at the Source SALT LAKE CITY, May 28, 2025--(BUSINESS WIRE)--As alarming new research reveals microplastics accumulating in the human brain—especially in individuals with dementia—Echo is offering a practical solution that starts at the tap: advanced filtration technology designed to reduce harmful contaminants, including microplastics. A recent study in Nature Medicine (2025) found significant levels of microplastics in the brain tissue of 52 deceased individuals. On average, each brain contained approximately 7 grams of plastic—roughly the weight of a plastic spoon. Individuals with dementia had up to three times more microplastics than those without cognitive decline. Most concerning, the study shows microplastic levels in brain tissue have increased by 50% since 2016, raising urgent questions about long-term effects on brain health and cognitive function. "Microplastics are no longer just an environmental concern—they're showing up in our bodies, likely contributing to inflammation, oxidative stress, and possibly even neurological damage," said Dr. Tyler W. LeBaron, MSc., Ph.D., founder and executive director of the Molecular Hydrogen Institute. "While we can't control all environmental factors, improving water quality is one of the most immediate and effective steps we can take. Thanks to advances in filtration technology, we now can reduce exposure to these invisible contaminants and protect our health for the long term." Given the growing body of evidence surrounding microplastic exposure, Echo has developed solutions that go beyond just drinking water—protecting your entire household from these harmful contaminants. Echo Pure™ Whole Home Water Filter The Echo Pure Whole Home Water Filter is a state-of-the-art, five-stage filtration system designed to deliver clean, contaminant-free water to every faucet, showerhead, and appliance in your home. This advanced system combines KDF-55 and KDF-85 with catalytic carbon to remove a wide range of contaminants, including microplastics, chlorine, chloramine, bacteria, viruses, PFAS, lead, and fluoride. Its innovative reticulated foam design ensures consistent contact with the filtration media, preventing channeling and maintaining optimal purification. Built with a durable fiberglass tank, the Echo Pure™ system is engineered for long-term performance, capable of filtering up to 1 million gallons of water, and backed by a 10-year warranty—offering families peace of mind with every drop. "Many people focus on the water they drink, but they often overlook the water they bathe in, the steam they breathe, and what their skin absorbs every day," said Josh Carr, CEO of Echo. "That's why whole-home filtration is so important—it's about protecting your health on all fronts. What's more, emerging research shows that hydrogen—already known for its health benefits—may also help the body to break down microplastics. It's exciting to see hydrogen technology contributing to solving one of the world's most pressing environmental issues." Echo is dedicated to providing clean, hydrogen-enriched water that promotes whole-body health. With over a decade of innovation and a focus on science-backed wellness, Echo is leading the way in functional water technology. To learn more about Echo's Whole Home Water Filter and the science behind cleaner, healthier water, visit About Echo Echo is a pioneer in hydrogen health, dedicated to helping people unlock and sustain peak performance by transforming water into a clean source of cellular support. From advanced home water systems to portable wellness solutions, Echo works with the body to promote internal balance, resilience, and consistent energy. Backed by peer-reviewed science, trusted by health experts, and engineered for everyday living, Echo makes hydrogen health accessible, effective, and transformative. For more information, visit View source version on Contacts Media Contact: Alex KoritzKORITZ Communications801-450-8005alex.k@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store